{"nctId":"NCT01766401","briefTitle":"Safety, Efficacy and Tolerability of Vilazodone in Patients With Generalized Anxiety Disorder","startDateStruct":{"date":"2013-01-31","type":"ACTUAL"},"conditions":["Generalized Anxiety Disorder"],"count":402,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Vilazadone","type":"EXPERIMENTAL","interventionNames":["Drug: Vilazadone"]}],"interventions":[{"name":"Placebo","otherNames":["Dose-matched placebo tablets, oral administration, once per day"]},{"name":"Vilazadone","otherNames":["Vilazadone once per day, 20 mg dose, oral administration or Vilazadone once per day, 40 mg dose, oral administration."]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female, 18 - 70 Years of age\n* Currently meet the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for Generalized Anxiety Disorder (GAD)\n* Minimum score of 20 on the Hamilton Rating Scale for Anxiety (HAM-A)\n\nExclusion Criteria:\n\n* Women who are pregnant, women who will be breastfeeding during the study, and women of childbearing potential who are not practicing a reliable method of birth control\n* Patients with a history of meeting DSM-IV-TR criteria for:\n\n  * any manic, hypomanic or mixed episode, including bipolar disorder and substance-induced manic, hypomanic, or mixed episode;\n  * any depressive episode with psychotic or catatonic features;\n  * panic disorder with or without agoraphobia;\n  * obsessive-compulsive disorder;\n  * Schizophrenia, schizoaffective, or other psychotic disorder;\n  * bulimia or anorexia nervosa;\n  * presence of borderline personality disorder or antisocial personality disorder;\n  * mental retardation, dementia, amnesia, or other cognitive disorders\n* Patients who are considered a suicide risk","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Baseline in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score","description":"The Hamilton Anxiety Rating Scale (HAM-A) is a clinician-administered scale which consists of 14 items, each rated on a five point scale ranging from 0 (not present) to 4 (very severe). The highest possible score is 56, which represents the most severe form of anxiety; the lowest possible score is 0, which represents an absence of anxiety.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.9","spread":"7.37"},{"groupId":"OG001","value":"13.5","spread":"7.41"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Sheehan Disability Scale (SDS) Total Score","description":"The Sheehan Disability Scale (SDS) is a 3-item clinician-rated questionnaire used to evaluate impairments in the domains of work, social life/leisure, and family life/home responsibility. All items are rated on an 11-point continuum (0 = no impairment to 10 = most severe) with the total SDS score ranging from 0 (no impairment) to 30 (most severe).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.1","spread":"6.58"},{"groupId":"OG001","value":"7.8","spread":"6.91"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":198},"commonTop":["Diarrhoea","Nausea","Headache","Dizziness","Dry mouth"]}}}